Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Unternehmen & Branche
| Name | Celcuity Inc. |
|---|---|
| Ticker | CELC |
| CIK | 0001603454 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 8071 · Services-Medical Laboratories |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 5,83 Mrd. USD |
| Beta | 0,42 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -177,042,000 | -3.79 | 466,558,000 | 100,555,000 | |
| 2025-09-30 | 10-Q | -43,804,000 | -0.92 | 476,004,000 | 116,963,000 | |
| 2025-06-30 | 10-Q | -45,268,000 | -1.04 | 183,592,000 | 44,375,000 | |
| 2025-03-31 | 10-Q | -36,997,000 | -0.86 | 218,127,000 | 86,668,000 | |
| 2024-12-31 | 10-K | -111,779,000 | -2.83 | 245,123,000 | 115,619,000 | |
| 2024-09-30 | 10-Q | -29,792,000 | -0.70 | 273,036,970 | 149,709,000 | |
| 2024-06-30 | 10-Q | -23,722,000 | -0.62 | 292,544,985 | 176,685,000 | |
| 2024-03-31 | 10-Q | -21,612,000 | -0.64 | 188,181,054 | 133,737,000 | |
| 2023-12-31 | 10-K | -63,779,116 | -2.69 | 191,219,398 | 139,769,000 | |
| 2023-09-30 | 10-Q | -18,404,540 | -0.83 | 142,384,181 | 92,896,440 | |
| 2023-06-30 | 10-Q | -14,587,687 | -0.66 | 153,517,191 | 110,132,341 | |
| 2023-03-31 | 10-Q | -11,938,417 | -0.55 | 164,874,958 | 123,226,768 | |
| 2022-12-31 | 10-K | -40,370,040 | -2.64 | 175,697,097 | 133,771,467 | |
| 2022-09-30 | 10-Q | -10,893,721 | -0.75 | 65,291,650 | 43,525,341 | |
| 2022-06-30 | 10-Q | -9,960,526 | -0.67 | 72,350,187 | 53,188,731 | |
| 2022-03-31 | 10-Q | -7,934,447 | 79,929,855 | 61,539,715 | ||
| 2021-12-31 | 10-K | -29,605,266 | 85,906,320 | 68,710,477 | ||
| 2021-09-30 | 10-Q | -6,027,246 | 91,837,600 | 74,474,386 | ||
| 2021-06-30 | 10-Q | -14,032,852 | 42,809,329 | 27,034,524 | ||
| 2021-03-31 | 10-Q | -2,791,668 | 36,367,061 | 35,174,544 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-27 | Dalvey David | Director | Open Market Sale | -20,000 | 120.03 | -2,400,538.00 | -168,2% | |
| 2025-12-05 | Buller Richard E | Director | Open Market Sale | -1,510 | 106.04 | -160,113.30 | -11,2% | |
| 2025-12-05 | Buller Richard E | Director | Open Market Sale | -1,490 | 105.34 | -156,956.30 | -11,0% | |
| 2025-12-01 | Buller Richard E | Director | Open Market Sale | -1,100 | 98.13 | -107,948.39 | -7,6% | |
| 2025-11-21 | Dalvey David | Director | Open Market Sale | -15,000 | 100.00 | -1,500,016.50 | -105,1% | |
| 2025-11-20 | Buller Richard E | Director | Open Market Sale | -3,900 | 96.73 | -377,254.80 | -26,4% | |
| 2025-09-08 | BAKER BROS. ADVISORS LP | 10% Owner | Open Market Purchase | 388 | 58.02 | 22,513.16 | +1,6% | |
| 2025-09-08 | BAKER BROS. ADVISORS LP | 10% Owner | Open Market Purchase | 151,524 | 56.22 | 8,518,679.28 | +596,8% | |
| 2025-09-08 | BAKER BROS. ADVISORS LP | 10% Owner | Open Market Purchase | 13,976 | 56.22 | 785,730.72 | +55,0% | |
| 2025-09-08 | BAKER BROS. ADVISORS LP | 10% Owner | Open Market Purchase | 4,212 | 58.02 | 244,395.40 | +17,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.